这项研究表明，CAR-E有选择性地增强了CAR-T细胞的功能和持久性。该方法提供了一种现成的治疗选择，允许优化剂量和治疗方案，以最大程度地减少 ...

Carisma Therapeutics is developing a unique, differentiated immuno-oncology (IO) treatment for solid tumors based on chimeric antigen receptor macrophages (CAR-M). Current IO treatments have ...

近年来，CAR-T免疫疗法除了被用来治疗急性白血病和非霍奇金淋巴瘤之外，经改进后，也被用来治疗实体瘤、自身免疫疾病、HIV感染和心脏病等疾病 ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives ...

Research team led by Park Ji-hoon at the Korea Research Institute of Chemical Technology has produced "CAR-M" (Chimeric Antigen Receptor Macrophages) by stably inserting anti-cancer genes into ...

Macrophages serve as the Swiss army knives of the innate immune system, switching between phenotypes to perform different functions in response to the surrounding environment. One of their key ...

They are focused on proprietary CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages. Macrophages have ability to easily ...